852801-93-5

Upstream product

• 852802-35-8 tert-butyl 2-[4-amino-2-[(aminooxy)methyl]-7-(benzyloxy)-1H-imidazo[4,5-c]quinolin-1-yl]ethylcarbamate 
• 67-64-1 acetone 
• 749922-34-7 7-(benzyloxy)quinolin-4-ol 
• 749922-36-9 2-{[7-(benzyloxy)-3-nitroquinolin-4-yl]amino}ethanol 
• 749922-35-8 7-(benzyloxy)-3-nitroquinolin-4-ol 
• 749922-33-6 5-{[(3-benzyloxy)phenylimino]methyl}-2,2-dimethyl-[1,3]-dioxane-4,6-dione 
• 847578-83-0 tert-butyl 2-[(3-amino-7-benzyloxyquinolin-4-yl)amino]ethylcarbamate 
• 847578-82-9 tert-butyl 2-{[7-(benzyloxy)-3-nitroquinolin-4-yl]amino}ethylcarbamate 
• 847578-84-1 tert-butyl 2-[7-(benzyloxy)-2-(chloromethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethylcarbamate 
• 852802-33-6 tert-butyl 2-[4-amino-7-(benzyloxy)-2-(chloromethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethylcarbamate 
• 1484-26-0 3-(benzyloxy)aniline 

Relevant academic research and scientific papers

OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS

Imidazo ring compounds (e.g., imidazoquinolines, 6,7,8,9-tetrahydroimidazoquinolines, imidazonaphthyridines, and imidazopyridines) with an oxime substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.